Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells

Oncotarget

Volumn 4, Issue 2, 2013, Pages 218-230

  Roscher, Mareike ^a   Hormann, Inis ^a   Leib, Oliver ^b   Marx, Sebastian ^b   Moreno, Josue ^b   Miltner, Erich ^a   Friesen, Claudia ^a  

^a UNIVERSITY OF ULM   (Germany)

^b ITG Isotope Technologies Garching GmbH   (Germany)

Author keywords

Anti CD20; Apoptosis; Bismuth 213; Non Hodgkin lymphoma; Radioresistance; Targeted alpha therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BISMUTH CD20 ANTIBODY BI 213; CASPASE 2; CASPASE 3; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ALPHA RADIATION; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOMA CELL; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; PROTEIN CLEAVAGE;

EID: 84875792991     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.817     Document Type: Article

References (54)

1. Allen BJ. Can alpha-radioimmunotherapy increase efficacy for the systemic control of cancer? Immunotherapy. 2011; 3(4):455-458.
2. Shan D, Ledbetter JA and Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998; 91(5):1644-1652.
3. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF and Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984; 63(6):1424-1433.
4. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF and Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981; 67(1):134-140.
5. Oflazoglu E and Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs. 2(1):14-19.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998.16(8)2825-2833.
7. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK and Press OW. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007; 67(12):5921-5928.
8. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA and Kearsley J. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2005; 4(12):1318-1324.
9. Dadachova E, Bryan RA, Apostolidis C, Morgenstern A, Zhang T, Moadel T, Torres M, Huang X, Revskaya E and Casadevall A. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis. 2006; 193(10):1427-1436.
10. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A and Goldstein H. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 2006; 3(11):e427.
11. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R and Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002; 100(4):1233-1239.
12. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ and Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008; 49(1):30-38.
13. Friesen C, Herr I, Krammer PH and Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996; 2(5):574-577.
14. Timmer JC and Salvesen GS. Caspase substrates. Cell Death Differ. 2007; 14(1):66-72.
15. Ogawa K, Murayama S and Mori M. Predicting the tumor response to radiotherapy using microarray analysis (Review). Oncol Rep. 2007; 18(5):1243-1248.
16. Friesen C, Fulda S and Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997; 11(11):1833-1841.
17. Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009; 124(3):511-515.
18. Danial NN and Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116(2):205-219.
19. Green DR and Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004; 305(5684):626-629.
20. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003; 17(20):2481-2495.
21. Szegezdi E, Macdonald DC, Ní Chonghaile T, Gupta S and A S. Bcl-2 family on guard at the ER. Am J Physiol Cell Physiol. 2009; 296(5):12.
22. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M and Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000; 6(5):1796-1803.
23. Loeder S, Drensek A, Jeremias I, Debatin KM and Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer. 126(9):2216-2228.
24. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, Debatin KM and Reske SN. Breaking chemoresistance and radioresistance with [213Bi]anti CD45 antibodies in leukemia cells. Cancer Res. 2007;67(5):1950-1958.
25. Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ and WH K. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur J Nucl Med Mol Imaging. 2010; 37(5):10.
26. Seidl C, Port M, Apostolidis C, Bruchertseifer F, Schwaiger M, Senekowitsch-Schmidtke R and Abend M. Differential gene expression triggered by highly cytotoxic alpha-Emitter-immunoconjugates in gastric cancer cells. Invest New Drugs. 2009; 6(8):2346-2359.
27. Vandenbulcke K, De Vos F, Offner F, Philippe J, Apostolidis C, Molinet R, Nikula TK, Bacher K, de Gelder V, Vral A, Lahorte C, Thierens H, Dierckx RA and Slegers G. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging. 2003; 30(10):1357-1364.
28. Vandenbulcke K, Thierens H, Offner F, Janssens A, de Gelder V, Bacher K, Philippe J, De Vos F, Dierckx R, Apostolidis C, Morgenstern A and Slegers G. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study. Nucl Med Commun. 2004; 25(11):1131-1136.
29. Bryan RA, Huang X, Morgenstern A, Bruchertseifer F, Casadevall A and Dadachova E. Radiofungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans. Antimicrob Agents Chemother. 2008; 52(6):2232-2235.
30. Tokalov SV and Iagunov AS. Radiation-induced cell cycle arrests in Ehrlich ascites carcinoma cells in vivo. Radiat Environ Biophys. 50(2):265-270.
31. Li J and Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48):6194-6206
32. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008; 27(48):6252-6275.
33. Cory S and Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002; 2(9):647-656.
34. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA and Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. 1992; 148(4):1149-1154.
35. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993; 328(14):1023-1030.
36. Johnson TA and Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol. 2000; 79(4):175-182.
37. Weiner GJ and Link BK. Monoclonal antibody therapy of B cell lymphoma. Expert Opin Biol Ther. 2004; 4(3):375-385.
38. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G and Wahl RL. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000; 96(4):1259-1266.
39. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S and Wahl RL. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352(5):441-449.
40. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS and White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximabrefractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20(15):3262-3269.
41. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Back T, Lin Y, Fisher DR, Gopal AK, Green DJ and Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010; 116(20):4231-4239.
42. Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 2007; (43):4918-4928.
43. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM and Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341-1351.
44. Aurlien E, Kvinnsland Y, Larsen RH and Bruland OS. Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gammairradiation. Int J Radiat Biol. 2002; 78(2):133-142.
45. Aurlien E, Larsen RH, Kvalheim G and Bruland OS. Demonstration of highly specific toxicity of the alphaemitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer. 2000; 83(10):1375-1379.
46. Bratton SB and Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 123(Pt 19):3209-3214.
47. Bai M, Papoudou-Bai A, Kitsoulis P, Horianopoulos N, Kamina S, Agnantis NJ and Kanavaros P. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas. In Vivo. 2005;19(2):439-453.
48. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkoppele GJ, Gundy C, Meijer CJ and Oudejans JJ. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005; 105(7):2916-2923.
49. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G, Tu Y, Stolovitzky GA, Califano A, Hansmann ML and Dalla-Favera R. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003; 111(4):529-537.
50. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ and Oudejans JJ. Smallmolecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood. 2008; 111(1):369-375.
51. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A and Dallaire BK. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999; 26(5 Suppl 14):66-73.
52. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51.
53. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139(2):271-279.
54. Carbonari M, Cibati M, Cherchi M, Sbarigia D, Pesce AM, Dell'anna L, Modica A and Fiorilli M. Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. Blood. 1994; 83(5):1268-1277.